BEXIMCO PHARMA.GDR REGS 1 (R2WA) — Cash Flow Quality Index
BEXIMCO PHARMA.GDR REGS 1 (R2WA) has a Cash Flow Quality Index of 1.43x as of June 2024. Operating cash flow of €8.36 Billion exceeds net income of €5.83 Billion, indicating high earnings quality where cash backs reported profits. Explore R2WA cash flow metrics to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
BEXIMCO PHARMA.GDR REGS 1 Cash Flow Quality Index (2022–2024)
Historical Cash Flow Quality Index for BEXIMCO PHARMA.GDR REGS 1 across 3 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check BEXIMCO PHARMA.GDR REGS 1 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for BEXIMCO PHARMA.GDR REGS 1 (2022–2024)
Year-by-year earnings quality comparison for BEXIMCO PHARMA.GDR REGS 1. For live market cap and the full company financial profile, see market cap of BEXIMCO PHARMA.GDR REGS 1.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.43x | €8.36 Billion | €5.83 Billion | ▲ +8.7% |
| 2023 | 1.32x | €6.08 Billion | €4.61 Billion | ▲ +29.6% |
| 2022 | 1.02x | €5.21 Billion | €5.12 Billion | — |